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to electronic health care records (EHR) data. Methods: Using GNS Health care’s 
analytical platform (REFSTM), we built unbiased predictive models for progression 
to T2D, computationally exploring trillions of potential models, in Humedica data. 
Humedica’s data acquisition model aggregates de-identified EHR from providers 
across the continuum of care. Our study population consisted of 24,331 adults 
without history of prediabetes or T2D, from 2007-2012. Prediabetes was defined 
using World Health Organization criteria; incident T2D was identified using ICD-9 
codes. Accuracy of prediction models was assessed using an area under the curve 
(AUC) statistic. We validated resulting prediction models in an independent data-
set. Results: Our baseline model accurately predicted progression to T2D from 
normoglycemia (AUC = 0.76). We validated this model with an independent data-
set where the AUC increased to 0.78. When the model was extended to include 
time-varying covariates the AUC increased to 0.87. Our model of progression from 
normoglycemia to T2D consisted of established risk factors (blood glucose meas-
ures, hypertension, income, race, triglycerides, lipid disorders, and blood pressure), 
whereas predictors of progression to prediabetes included novel factors such as 
high-density lipoprotein, alanine aminotransferase, C-reactive protein, and core 
body temperature (AUC = 0.70). ConClusions: Using an extensive EHR data-
base, we built accurate prediction models of diabetes risk using a hypothesis-free, 
machine-learning Bayesian approach, and validated them with an independent 
dataset. In doing so, we identified novel factors representing emerging areas of 
diabetes research and potential new targets for clinical management. Our ability 
to make individual T2D risk predictions has valuable applications to personalized 
medicine and clinical trial recruitment.
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objeCtives: Estimating the budget impact of the introduction of vildagliptin as 
addition to insulin in the treatment of patients with type 2 diabetes mellitus with 
inadequate glycemic control (HbA1c> 7%) compared to the same group of patients 
treated with insulin monotherapy in Colombia, from third-party payer perspec-
tive. Methods: Markov model, which simulates the natural history of the disease, 
budget impact analysis (AIP) was made under the Colombian context for a five-year 
period using direct health costs associated with the natural history of the disease, 
including macrovascular and microvascular events and episode of hypoglycemia 
in a mobile cohort of patients, looking at prevalence, incidence and death. In the 
alternative scenarios, it will estimate reductions in insulin doses for the correspond-
ing arm vildagliptin in addition to insulin. Direct health care costs were taken from 
insurers and individual records of health benefits (RIPS) 2012. Results: With a 
disease prevalence and incidence rate of 0.04 & 0.00879 respectively in Colombia 
and assuming that 8.6% of patients require insulin according to the stage of the dis-
ease, the cumulative cost to 5 years of patients treated with insulin alone, would be 
COP $3,030,742,552,215(USD1.565.522,80), compared to COP $3,546,840,289,383(USD 
1.832.111,85) treated with insulin + Vildagliptin. Additionally, contemplating a reduc-
tion of approximately 27% in the dose of insulin, savings were generated under the 
use of vildagliptin in addition to insulin from the third year on total cost as well as 
reduction of cardiovascular and adverse events. Similarly, savings accumulated over 
the capitation payment unit of 0.000093% in 5 years, accompanied by lower mortal-
ity. ConClusions: The use of vildagliptin in addition to insulin will be significantly 
less expensive than using insulin monotherapy for patients with type 2 diabetes 
with inadequate glycemic control, in the Colombian health system context, along 
with better health care outcomes.
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objeCtives: This post-hoc analysis estimated the budget impact of PHEN/TPM ER 
7.5/46 mg in comparison with lifestyle modification (LM) alone in overweight and 
obese patients with comorbid prediabetes or T2DM. Methods: A 1-year budget 
impact model was developed from the health plan perspective evaluating pharmacy 
costs and comorbidity costs in overweight and obese patients with prediabetes or 
T2DM. Changes in body mass index (BMI) for PHEN/TPM ER 7.5/46 and LM were 
based on data from CONQUER, a phase 3, 56-week randomized trial (Gadde 2011). 
Comorbidity cost offsets for BMI reductions were calculated by multiplying the 
change in BMI by medical ($164) and pharmacy ($113) costs per unit of BMI (Wang 
2006). The rate of progression from prediabetes to T2DM was based on data from 
CONQUER. Literature-based estimates of the annual cost of treating prediabetes 
($535) and T2DM ($8069) were used to calculate comorbidity costs. The plan popula-
tion was assumed to be 1,000,000 patients and the market uptake of PHEN/TPM ER 
7.5/46 was assumed to be 1% at a weighted cost per capsule of $5.04. Results: In 
patients with prediabetes, BMI was reduced by 4.30kg/m2 for PHEN/TPM ER 7.5/46 
and 2.15kg/m2 for LM, translating to annual cost offsets of $1191 and $596, respec-
tively. The rate of progression from prediabetes to T2DM was 3.8% for PHEN/TPM ER 
and 9.6% for LM. In patients with T2DM, the BMI reduction was 3.69kg/m2 for PHEN/
TPM ER and 1.96kg/m2 for LM, translating to cost offsets of $1022 and $543, respec-
tively. The budget impact of adding PHEN/TPM ER 7.5/46 therapy was $0.01 per mem-
ber per month (PMPM) for prediabetes and $0.05 PMPM for T2DM. ConClusions: 
The budget impact of adding weight management therapy with PHEN/TPM ER in 
overweight or obese patients with prediabetes or T2DM is minimal and is offset by 
reduced comorbidity costs.
adult (ages 20-79) diabetes patients in Africa, ~1.5 times the prevalence in 2003. The 
continent-wide expenditure on diabetes in 2013 was ~$7.06 billion, compared to 
$2.72 billion in 2010, accounting for ~1% of global expenditures despite a prevalence 
burden of nearly 10% of global figures. The highest proportion of diabetes cases and 
spending were from northern Africa (40.4% of cases, 41.8% expenditures in 2013). 
However, eastern Africa (23.2% cases, 7.1% expenditures), western Africa (19.3% 
cases, 10.9% expenditures), and central Africa (8.6% cases, 4.2% expenditures), shoul-
der higher burdens of disease than their share of expenditures. In contrast, southern 
Africa (8.4% cases, 36% expenditures) has a lower percentage of overall patients, but 
spends significantly more than other regions. Data indicate that access to diabetes 
treatment is highly variable by region, and that disease management programs are 
infrequently available. Drug therapies are more broadly available, though costs can 
be a significant barrier to utilization. ConClusions: Rising disease prevalence will 
continue to stimulate demand for medical solutions in Africa. Northern and south-
ern Africa present a noteworthy market opportunity due to high disease prevalence 
and/or relatively high mean spending per patient. Affordable solutions that account 
for the variability in local market economics and implementation infrastructure are 
needed to support the growing diabetes burden in Africa.
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objeCtives: The aim of this study was to examine the geographic, age, gender 
and racial variations in the prevalence of diabetes in the U.S. Medicaid popula-
tion. Methods: This retrospective study analyzed a patient sample from the 
Medicaid fee-for-service (FFS) population in 2008 and 2009. Patients diagnosed with 
diabetes were identified using International Classification of Disease, 9thRevision, 
Clinical Modification (ICD-9-CM) diagnosis codes 250.x0 and 250.x2. Continuous 
Medicaid FFS enrollment was required during the 2-year study period. Patients 
were excluded if they had managed care enrollment in any month during the study 
period. Diabetes prevalence was analyzed by region, state, age, gender and race. The 
number and percentages of patients in each category were provided in the descrip-
tive analysis. Results: A total of 817,596 patients (16.66%) were diagnosed with 
diabetes among the Medicaid FFS population in 2008 through 2009. Patients over 
age 60 years had a higher prevalence (23.00%) than those age 40-59 (19.53%) or 0-39 
years (3.27%). Prevalence was also examined by race, with the highest prevalence 
found in Asian patients (22.17%), followed by Black (20.42%), Hispanic (16.89%), White 
(15.91%) and Native American (8.89%) patients. Prevalence of diabetes was much 
higher for female (18.36%) than for male patients (13.99%). U.S. states with the 
highest prevalence were Maryland (27.42%), Connecticut (26.73%), North Carolina 
(25.72%), Ohio (23.99%) and Indiana (23.51%). Prevalence trends were also strati-
fied by U.S. region: Midwest (18.12%), South (17.11%), Northeast (16.59%) and West 
(7.60%). ConClusions: The study results illustrate that elderly patients had a 
higher probability of being diagnosed with diabetes. Asian patients were more likely 
to be diagnosed with diabetes compared to other races. Female patients were at a 
higher risk for diabetes. Patients who resided in the Midwest U.S. region also had 
an increased likelihood of a diabetes diagnosis.
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objeCtives: Diabetes mellitus (DM) screening using hemoglobin A1c (HbA1c) is 
important to identify those at risk of cardiovascular disease. Little information is 
available on strategies for monitoring including frequency and timing of re-screen-
ing. We aimed to estimate the long-term between-person variation (“signal”) and 
short-term within-person variation (“noise”) of the HbA1c measures and evaluated 
the optical interval of re-checking HbA1c levels for DM screening. Methods: We 
conducted a retrospective cohort study including enrolled all people who consecu-
tively visited the St. Luke’s International Hospital Centre for Preventive Medicine 
(Tokyo, Japan) for a health check-up between 2005 and 2010. We measured the serum 
HbA1c annually. We estimated the ratio of “signal” to “noise” for HbA1c, adjusting for 
age, gender, using the random effects model. When the ratio of signal to noise was 
> = 1, we considered that screening interval appropriate. Results: A total of 34,662 
apparently healthy Japanese adults not taking diabetes medication at baseline had 
annual check-ups over 5 years. The mean age of the participants was 49 years old 
(SD: 12, range: 21 to 95) and 52% were male. Mean systolic blood pressure and BMI 
were 118 mmHg (SD: 17 mmHg) and 22.7 kg/m2 (SD: 3.7), respectively. Mean HbA1c 
level was 5.6% mg/dl (SD: 0.5%). Short-term within-person variations of HbA1c was 
0.10 (coefficient of variation, 6.1%) and long-term between-person variation were 
0.06 at 5 years and 0.13 at 7 years, respectively. The ratios of signal to noise were 
0.63 at 5 years and 1.2 at 7 years, respectively. ConClusions: Our findings suggest 
that the optimal interval of DM screening for healthy adults should be more than 
5 years using HbA1c.
PDb27
iDentification of Determinants of Progression to tyPe 2 Diabetes 
using electronic health recorDs anD ‘big Data’ analytics
Anderson J.P.1, Parikh J.R.1, Shenfeld D.K.1, Church B.W.1, Laramie J.M.1, Piper B.A.2, Willke R.J.2, 
Mardekian J.2, Rublee D.A.2
1GNS Healthcare, Cambridge, MA, USA, 2Pfizer, Inc., New York, NY, USA
objeCtives: Type 2 diabetes (T2D) is strongly associated with morbidity and mor-
tality, and carries a heavy financial burden. An improved understanding of the 
factors that predict progression to prediabetes and T2D is warranted. Thus our 
objective was to identify these determinants, applying ‘big data’ analytic methods 
